Ellen Sidransky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ellen Sidransky has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Nahid Tayebi
Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, 20892-4405, USA
9 shared publications- Joseph K. Park
Gilead Sciences, Inc., Foster City, California
5 shared publications Deborah L. Stone
Clinical Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland
3 shared publicationsE. Orvisky
Clinical Neuroscience Branch, NIMH, National Institutes of Health, Bethesda, MD, USA
3 shared publicationsEduard Orvisky
3 shared publicationsEdward I. Ginns
Clinical Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland
3 shared publications
Latest Publications
- Open Access
- 23 July 2010
- Published by Bentham Science Publishers Ltd. in Current Chemical Genomics
- Vol. 4 (1) , 50-56
Fabry Disease – Current Treatment and New Drug Development
Fabry Disease – Current Treatment and New Drug Development
- 23 July 2010
- Published by Bentham Science Publishers Ltd. in Current Chemical Genomics
- Vol. 4 (1) , 50-56
Open AccessFabry Disease – Current Treatment and New Drug Development
Fabry Disease – Current Treatment and New Drug Development
- 8 February 2006
- Published by Wiley in Movement Disorders
- Vol. 21 (2) , 282-283
Glucocerebrosidase mutations are also found in subjects with early‐onset parkinsonism from Venezuela
- 8 February 2006
- Published by Wiley in Movement Disorders
- Vol. 21 (2) , 282-283
Glucocerebrosidase mutations are also found in subjects with early‐onset parkinsonism from Venezuela
- 5 August 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 26 (3) , 271-273
Gaucher mutation N188S is associated with myoclonic epilepsy
The recent article by Montfort et al. [2004] reported a functional analysis of 13 glucocerebrosidase alleles, including mutation N188S, which they considered to be a “very mild mutation” or “modifier variant.” Our clinical experience with patients carrying this mutation and preliminary protein modeling data lead us to dispute this conclusion. Hum Mutat 26(3), 271–273, 2005.
- 5 August 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 26 (3) , 271-273
Gaucher mutation N188S is associated with myoclonic epilepsy
The recent article by Montfort et al. [2004] reported a functional analysis of 13 glucocerebrosidase alleles, including mutation N188S, which they considered to be a “very mild mutation” or “modifier variant.” Our clinical experience with patients carrying this mutation and preliminary protein modeling data lead us to dispute this conclusion. Hum Mutat 26(3), 271–273, 2005.
- Open Access
- 3 June 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (6) , e37
Divergent phenotypes in Gaucher disease implicate the role of modifiers
Background: Gaucher disease is classified into neuronopathic and non-neuronopathic forms with wide phenotypic variation among patients sharing the same genotype. While homozygosity for the common L444P allele usually correlates with the neuronopathic forms, how a defined genotype leads to a phenotype remains unknown. Methods: The genetic and epigenetic factors causing phenotypic differences were approached by a clinical association study in 32 children homozygous for the point mutation L444P. Direct sequencing and Southern blots were utilised to establish the genotype and exclude recombinant alleles. Glucocerebrosidase activity was measured in lymphoblast and fibroblast cell lines. Results: Residual enzyme activity was highly variable and did not correlate with the observed clinical course. There was also a wide spectrum of phenotypes. Average age at diagnosis was 15 months, and slowed saccadic eye movements were the most prevalent finding. The most severe systemic complications and highest mortality occurred in splenectomised patients before the advent of enzyme replacement therapy (ERT). On ERT, as morbidity and mortality decreased, developmental and language deficits emerged as a major issue. Some trends related to ethnic background were observed. Conclusion: The wide clinical spectrum observed in the L444P homozygotes implicates the contribution of genetic modifiers in defining the phenotype in Gaucher disease.
- 3 June 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (6) , e37
Open AccessDivergent phenotypes in Gaucher disease implicate the role of modifiers
Background: Gaucher disease is classified into neuronopathic and non-neuronopathic forms with wide phenotypic variation among patients sharing the same genotype. While homozygosity for the common L444P allele usually correlates with the neuronopathic forms, how a defined genotype leads to a phenotype remains unknown. Methods: The genetic and epigenetic factors causing phenotypic differences were approached by a clinical association study in 32 children homozygous for the point mutation L444P. Direct sequencing and Southern blots were utilised to establish the genotype and exclude recombinant alleles. Glucocerebrosidase activity was measured in lymphoblast and fibroblast cell lines. Results: Residual enzyme activity was highly variable and did not correlate with the observed clinical course. There was also a wide spectrum of phenotypes. Average age at diagnosis was 15 months, and slowed saccadic eye movements were the most prevalent finding. The most severe systemic complications and highest mortality occurred in splenectomised patients before the advent of enzyme replacement therapy (ERT). On ERT, as morbidity and mortality decreased, developmental and language deficits emerged as a major issue. Some trends related to ethnic background were observed. Conclusion: The wide clinical spectrum observed in the L444P homozygotes implicates the contribution of genetic modifiers in defining the phenotype in Gaucher disease.
- 1 April 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 84 (4) , 302-304
Gaucher disease and parkinsonism
- 1 April 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 84 (4) , 302-304
Gaucher disease and parkinsonism
- 17 February 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (7) , 728-731
The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
The article by Aharon-Peretz et al. (Nov. 4 issue)1 is of considerable interest to us because it substantiates our previously published study2 in which glucocerebrosidase mutations were identified in brain samples from patients with parkinsonism. Autopsy samples from 57 patients with pathologically confirmed Parkinson's disease and 44 controls were screened by sequencing the entire glucocerebrosidase gene. Eight samples from the patients (14 percent) had glucocerebrosidase mutations, as compared with none of the samples from the control group. In addition, we recently sequenced 26 brain samples (from the U.K. Parkinson's Disease Society Tissue Bank at Imperial College, London) from patients in whom Parkinson's disease had been diagnosed between the ages of 42 and 78 years and found 2 (8 percent) that carried glucocerebrosidase mutations (D140H in 1 and RecNciI in the other).3 These findings, based on definitive diagnoses at autopsy, suggest that heterozygosity for mutations in the glucocerebrosidase gene may be a risk factor for parkinsonism among groups other than Ashkenazim. Since 4 of our 10 positive samples had mutations other than N370S and L444P, gene sequencing appears to be required to determine the true frequency of this association.
- 17 February 2005
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (7) , 728-731
The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
The article by Aharon-Peretz et al. (Nov. 4 issue)1 is of considerable interest to us because it substantiates our previously published study2 in which glucocerebrosidase mutations were identified in brain samples from patients with parkinsonism. Autopsy samples from 57 patients with pathologically confirmed Parkinson's disease and 44 controls were screened by sequencing the entire glucocerebrosidase gene. Eight samples from the patients (14 percent) had glucocerebrosidase mutations, as compared with none of the samples from the control group. In addition, we recently sequenced 26 brain samples (from the U.K. Parkinson's Disease Society Tissue Bank at Imperial College, London) from patients in whom Parkinson's disease had been diagnosed between the ages of 42 and 78 years and found 2 (8 percent) that carried glucocerebrosidase mutations (D140H in 1 and RecNciI in the other).3 These findings, based on definitive diagnoses at autopsy, suggest that heterozygosity for mutations in the glucocerebrosidase gene may be a risk factor for parkinsonism among groups other than Ashkenazim. Since 4 of our 10 positive samples had mutations other than N370S and L444P, gene sequencing appears to be required to determine the true frequency of this association.
- Open Access
- 9 December 2004
- Published by BMJ in Journal of Medical Genetics
- Vol. 41 (12) , 937-940
Parkinsonism among Gaucher disease carriers
An association between Gaucher disease and Parkinson disease has been demonstrated by the concurrence of Gaucher disease and parkinsonism in rare patients and the identification of glucocerebrosidase mutations in probands with sporadic Parkinson disease. Using a different and complementary approach, we describe 10 unrelated families of subjects with Gaucher disease where obligate or confirmed carriers of glucocerebrosidase mutations developed parkinsonism. These observations indicate that mutant glucocerebrosidase, even in heterozygotes, may be a risk factor for the development of parkinsonism. Understanding the relationship between altered glucocerebrosidase and the development of parkinsonian manifestations will provide insights into the genetics, pathogenesis, and treatment of Parkinson disease.
- 9 December 2004
- Published by BMJ in Journal of Medical Genetics
- Vol. 41 (12) , 937-940
Open AccessParkinsonism among Gaucher disease carriers
An association between Gaucher disease and Parkinson disease has been demonstrated by the concurrence of Gaucher disease and parkinsonism in rare patients and the identification of glucocerebrosidase mutations in probands with sporadic Parkinson disease. Using a different and complementary approach, we describe 10 unrelated families of subjects with Gaucher disease where obligate or confirmed carriers of glucocerebrosidase mutations developed parkinsonism. These observations indicate that mutant glucocerebrosidase, even in heterozygotes, may be a risk factor for the development of parkinsonism. Understanding the relationship between altered glucocerebrosidase and the development of parkinsonian manifestations will provide insights into the genetics, pathogenesis, and treatment of Parkinson disease.
- 1 September 2004
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 83 (1-2) , 6-15
Gaucher disease: complexity in a “simple” disorder
- 1 September 2004
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 83 (1-2) , 6-15
Gaucher disease: complexity in a “simple” disorder
- 13 March 2004
- Published by Springer Nature in Journal of Human Genetics
- Vol. 49 (4) , 220-222
A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 13 March 2004
- Published by Springer Nature in Journal of Human Genetics
- Vol. 49 (4) , 220-222
A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 22 April 2003
- Published by Elsevier in Analytical Biochemistry
- Vol. 317 (1) , 12-18
Phosphomannomutase activity in congenital disorders of glycosylation type Ia determined by direct analysis of the interconversion of mannose-1-phosphate to mannose-6-phosphate by high-pH anion-exchange chromatography with pulsed amperometric detection
- 22 April 2003
- Published by Elsevier in Analytical Biochemistry
- Vol. 317 (1) , 12-18
Phosphomannomutase activity in congenital disorders of glycosylation type Ia determined by direct analysis of the interconversion of mannose-1-phosphate to mannose-6-phosphate by high-pH anion-exchange chromatography with pulsed amperometric detection